ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH: /D.K./

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 4

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Dale B. Schenk |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

## U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | U.S. Patent Document Number | U.S. Patent Document Kind Code[2] (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | | | | | | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document Office[3] | Number[4] | Kind Code[5] (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| | 47 | EP | 526 511 | B1 | | 05-28-1997 | | ☐ |
| | 92 | GB | 2 220 211 | A | | 01-04-1990 | | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3154027 v2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 3

| *Complete if Kn wn* | |
|---|---|
| **Application Number** | 09/322,289 |
| **Filing Date** | May 28, 1999 |
| **First Named Inventor** | Dale B. Schenk |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

## U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No.[1] | U.S. Patent Document Number | U.S. Patent Document Kind Code[2] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | 196 | 6,150,091 | | Pandolfo et al. | 11-21-2000 | |
| | 1 | 6,057,367 | | Stamler et al. | 05-02-2000 | |
| | 207 | 5,780,587 | | Potter | 07-14-1998 | |
| | 197 | 5,744,368 | | Goldgaber et al. | 04-28-1998 | |
| | 211 | 5,736,142 | | Sette et al. | 04-07-1998 | |
| | 175 | 5,441,870 | | Seubert, et al. | 08-15-1995 | |
| | 181 | 5,270,165 | | Van Nostrand et al. | 12-14-1993 | |
| | 32 | 5,187,153 | | Cordell et al. | 02-16-93 | |
| | 198 | 5,004,697 | | Pardridge | 04-0201991 | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document Office[3] | Number[4] | Kind Code[5] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| | 187 | EP | 783 104 | A1 | | 07-09-1997 | | ☐ |
| | 199 | PCT | 00/77178 | A1 | | 12-21-2000 | | ☐ |
| | 188 | PCT | 00/43049 | A1 | | 07-27-2000 | | ☐ |
| | 58 | PCT | 99/27944 | A1 | | 06-10-1999 | | ☐ |
| | 203 | PCT | 99/00150 | A2 | | 01-07-1999 | | ☐ |
| | 202 | PCT | 97/21728 | A1 | | 06-19-1997 | | ☐ |
| | 208 | PCT | 96/28471 | A1 | | 09-19-1996 | | ☐ |
| | 200 | PCT | 95/12815 | A1 | | 05-11-1995 | | ☐ |
| | 201 | PCT | 94/28412 | A1 | | 12-08-1994 | | ☐ |
| | 205 | PCT | 93/04194 | A1 | | 03-04-1993 | | ☐ |
| | 87 | PCT | 89/01343 | A1 | | 02-23-1989 | | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

| FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | Attorney Docket No.: 15270-004740US<br>Applicant: Dale B. Schenk<br>Filing Date: May 28, 1999 | | Application No.: 09/322,289<br>Group: 1648 | |
|---|---|---|---|---|---|---|
| BH75 | WO 93/15760 | 8/19/93 | PCT | | | |
| BI76 | WO 93/14200 | 7/22/93 | PCT | | | |
| BJ77 | WO 93/02189 | 2/4/93 | PCT | | | |
| BK79 | WO 92/06708 | 4/30/92 | PCT | | | |
| BL80 | WO 92/06187 | 4/16/92 | PCT | | | |
| BM81 | WO 91/19810 | 12/26/91 | PCT | | | |
| BN82 | WO 91/16819 | 11/14/91 | PCT | | | |
| BO83 | WO 91/12816 | 9/5/91 | PCT | | | |
| BP84 | WO 91/08760 | 6/27/91 | PCT | | | |
| BQ85 | WO 90/12871 | 11/1/90 | PCT | | | |
| BR86 | WO 90/12870 | 11/1/90 | PCT | | | |
| BS88 | WO 89/06242 | 7/13/89 | PCT | | | |
| BT89 | WO 89/06689 | 7/27/89 | PCT | | | |
| BU91 | WO 88/10120 | 12/29/88 | PCT | | | |
| BV48 | EP 506 785 | 3/15/00 | Europe | | | |
| BW43 | EP 639 081 | 11/3/99 | Europe | | | |
| BX46 | EP 561 087 | 8/4/99 | Europe | | | |
| BY35 | EP 911 036 | 4/28/99 | Europe | | | |
| BZ42 | EP 652 962 | 12/16/98 | Europe | | | |
| CA37 | EP 863 211 | 9/9/98 | Europe | | | |
| CB38 | EP 845 270 | 6/3/98 | Europe | | | |
| CC45 | EP 594 607 | 8/27/97 | Europe | | | |
| CD39 | EP 782 859 | 7/9/97 | Europe | | | |
| CE50 | EP 440 619 | 1/24/96 | Europe | | | |
| CF51 | EP 359 783 | 11/29/95 | Europe | | | |
| CG40 | EP 683 234 | 11/22/95 | Europe | | | |
| CH41 | EP 666 080 | 8/9/95 | Europe | | | |
| CI49 | EP 451 700 | 10/16/91 | Europe | | | |
| CJ93 | GB 2 335 192 | 9/15/99 | United Kingdom | | | |
| | | | | | | |

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**

| | |
|---|---|
| CK94 | Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," Neurology, 45:1441-1445 (1995). |
| CL95 | Associated Press, "Immune cells may promote Alzehimer's, a study finds," *The Boston Globe* (4/13/95). |
| CM96 | Bauer et al., "Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," FEBS Letters, 285(1):111-114 (1991). |
| CN98 | Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," Biochem. Biophys. Res. Comm., 171(2):890-897 (1990). |
| CO97 | Blass, John P., "Immunologic Treatment of Alzheimer's Disease," New England J. Medicine, 341(22):1694 (1999). |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

| FORM PTO-1449 (Modified)<br>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Attorney Docket No.: 15270-004740US | Application No.: 09/322,289 |
|---|---|---|
| | Applicant: Dale B. Schenk | |
| | Filing Date: May 28, 1999 | Group: 1648 |

| | |
|---|---|
| CP 101 | Brice et al., "Absense of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," J. Neurology, Neurosurg. Psychiatry, 56:112-115 (1993). |
| CQ 102 | Chao et al., "Transforming Growth Factor-β Protects human Neurons Against β-Amyloid-Induced Injury," Soc. Neurosci. Abstracts, 19:513.7 (1993). |
| CR 105 | Felsenstein et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," Neuroscience Letters, 152:185-189 (1993). |
| CS 106 | Finch et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," Neurobiology of Aging, 17(5):809-815 (1996). |
| CT 107 | Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," PNAS, 88:1779-1782 (1991). |
| CU 108 | Flanders et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," Neurology, 45:1561-1569 (1995). |
| CV 110 | Gandy et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," TiPS, 13:108-113 (1992). |
| CW 115 | Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," Nature, 349:704-706 (1991). |
| CX 116 | Gozes et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," PNAS, 93:427-432 (1996). |
| CY 118 | Haga et al., "Synthetic Alzheimer amyloid β/A4 peptides enhance production of complement C3 component by cultured microglial cells," Brain Research, 601:88-94 (1993). |
| CZ 121 | Hardy, John, "New Insights into the Genetics of Alzheimer's Disease," Annals of Med., 28:255-258 (1996). |
| DA 123 | Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," J. Neuroimmunology, 52:147-152 (1994). |
| DB 124 | Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," N. E. J. Medicine, 333(19):1283-1284 (1995). |
| DC 125 | Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," J. Neuroimmunology, 24:173-182 (1989). |
| DD 127 | Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," Res. Immunology, 143:637-641 (1992). |
| DE 128 | Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," Nature, 354:476-478 (1991). |
| DF 129 | Lampert-Etchells et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," Neurodegeneration, 2:111-121 (1993). |
| DG 131 | Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," Behavioural Brain Res., 57:207-213 (1993). |
| DH 136 | Meda et al., "Activation of microglial cells by β-amyloid protein and interferon-γ," Nature, 374:647-650 (1995). |
| DI 137 | Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," J. Exp. Med., 174:791-798 (1991). |
| DJ 139 | New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94). |
| DK 143 | Quon et al., "Formation of β-Amyloid protein deposits in brains of transgenic mice," Nature, 352:239-241 (1991). |
| DL 146 | Rogers et al., "Complement activation by β-amyloid in Alzheimer Disease," PNAS, 89:1-5 (1992). |
| DM 147 | Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," Annals of New York Academy of Sciences, 695:198-202 (1993). |
| DN 152 | Selkoe, Dennis J., "Amyloid Protein and Alzheimer's Disease....," Scientific American, pgs. 68-78 (11/91). |
| DO 153 | Selkoe, Dennis J., "In the Beginning...," Nature, 354:432-433 (1991). |
| DP 154 | Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," Neuron, 6:487-498 (1991). |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

| FORM PTO-1449 (Modified)<br>LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Attorney Docket No.: 15270-004740US | Application No.: 09/322,289 |
|---|---|---|
| | Applicant: Dale B. Schenk | |
| | Filing Date: May 28, 1999 | Group: 1648 |

| | |
|---|---|
| _____ DQ 155 | Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," Science, 275:630-631 (1997). |
| _____ DR 157 | Shiosaka, Sadao, "Attempts to make models for Alzheimer's disease," Neuroscience Res., 13:237-255 (1992). |
| _____ DS 162 | Solomon, B., "New Approach Towards Fast Induction of Anti β-Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, ramat Aviv, Tel-Aviv, Israel. (PUBLICATION DATE UNKNOWN) |
| _____ DT 165 | Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," European J. Pharmacology, 352:135-142 (1998). |
| _____ DU 166 | Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," Immunobiology, 191(2-3):114-115 Abstract C.37, (1994). |
| _____ DV 168 | Verbeek et al., "Accumulation of Intercellular Adheasion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," Amer. Journ. Pathology, 144(1):104-116 (1994). |
| _____ DW 169 | Walker et al., "Labeling of Cerebral Amyloid *In Vivo* with a Monoclonal Antibody," J. Neuropath. Exp. Neurology, 53(4):377-383 (1994). |
| _____ DX 171 | Weiner et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12:809-837 (1994). |
| | |

| EXAMINER | DATE CONSIDERED |
|---|---|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

| FORM PTO-1449 (Modified) | Attorney Docket No.: 15270-004740US | Application No.: 09/322,289 |
|---|---|---|
| LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | Applicant: Dale B. Schenk | |
| | Filing Date: May 28, 1999 | Group: 1648 |

Reference Designation — **U.S. PATENT DOCUMENTS** — Page 1

| Examiner Initial | Document No. | Date | Name | Class | Sub-class | Filing Date (If Appropriate) |
|---|---|---|---|---|---|---|
| ____ AA 3 | 5,955,317 | 9/21/99 | Suzuki et al. | | | |
| ____ AB 4 | 5,955,079 | 9/21/99 | Mond et al. | | | |
| ____ AC 6 | 5,869,093 | 2/9/99 | Weiner et al. | | | |
| ____ AD 7 | 5,869,054 | 2/9/99 | Weiner et al. | | | |
| ____ AE 8 | 5,854,204 | 12/29/98 | Findeis et al. | | | |
| ____ AF 10 | 5,849,298 | 12/15/98 | Weiner et al. | | | |
| ____ AG 12 | 5,786,180 | 7/28/98 | Konig et al. | | | |
| ____ AH 14 | 5,750,349 | 5/12/98 | Suzuki et al. | | | |
| ____ AI 15 | 5,733,547 | 3/31/98 | Weiner et al. | | | |
| ____ AJ 16 | 5,688,651 | 11/18/97 | Solomon | | | |
| ____ AK 18 | 5,645,820 | 7/8/97 | Hafler et al. | | | |
| ____ AL 19 | 5,641,474 | 6/24/97 | Hafler et al. | | | |
| ____ AM 20 | 5,641,473 | 6/24/97 | Hafler et al. | | | |
| ____ AN 23 | 5,585,100 | 12/17/96 | Mond et al. | | | |
| ____ AO 24 | 5,571,500 | 11/5/96 | Hafler et al. | | | |
| ____ AP 25 | 5,571,499 | 11/5/96 | Hafler et al. | | | |
| ____ AQ 26 | 5,434,170 | 7/18/95 | Andrulis et al. | | | |
| ____ AR 27 | 5,387,742 | 2/7/95 | Cordell | | | |
| ____ AS 28 | 5,231,000 | 7/27/93 | Majocha et al. | | | |
| ____ AT 31 | 5,192,753 | 3/9/93 | McGeer et al. | | | |
| | | | | | | |

**FOREIGN PATENT DOCUMENTS**

| | Document No. | Date | Country | Class | Sub-class | Translation (Yes/No) |
|---|---|---|---|---|---|---|
| ____ AU 53 | WO 99/60024 | 11/25/99 | PCT | | | |
| ____ AV 54 | WO 99/60021 | 11/25/99 | PCT | | | |
| ____ AW 55 | WO 99/58564 | 11/18/99 | PCT | | | |
| ~~____ AX~~ | ~~WO 99/27949~~ | ~~6/10/99~~ | ~~PCT~~ Duplicate | | | |
| ____ AY 56 | WO 99/06066 | 2/11/99 | PCT | | | |
| ____ AZ 63 | WO 96/39176 | 12/12/96 | PCT | | | |
| ____ BA 64 | WO 96/25435 | 8/22/96 | PCT | | | |
| ____ BB 65 | WO 96/18900 | 6/20/96 | PCT | | | |
| ____ BC 66 | WO 95/31996 | 11/30/95 | PCT | | | |
| ____ BD 70 | WO 95/04151 | 2/9/95 | PCT | | | |
| ____ BE 71 | WO 94/03615 | 2/17/94 | PCT | | | |
| ____ BF 73 | WO 93/21950 | 11/11/93 | PCT | | | |
| ____ BG 74 | WO 93/16724 | 9/2/93 | PCT | | | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 2 of 3

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 204 | BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," Eur. J. Immunol. 29:345-354 (1999). | ☐ |
| | 212 | BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheomer's Diseases," Soc. for Neuroscience Abstracts 18:764 (1992). | ☐ |
| | 176 | BARD et al., "Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," Nature Medicine, 6(8):916-919 (2000). | ☐ |
| | 213 | CHEN et al. "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," Neuroscience Letters 125:223-226 (1991). | ☐ |
| | 214 | DEMATTOS et al., "Peripheral Anti Aβ Antibody Alters CNS And Plasma Aβ Clearance and Decreases Brain Aβ Burden in a Mouse Model of Alzheimer's Disease," Proc. Natl. Acad. Sci. USA, 10.1073/pnas.151261398 (2001). | ☐ |
| | 210 | Friedland et al., "'Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," Mol. Neurology, 9:107-113 (1994). | ☐ |
| | 215 | GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with $A\beta_{1-42}$," Annals of the New York Academy of Science 920:274-84 (2000). | ☐ |
| | 190 | GRAVINA et al., "Amyloid β Protein (Aβ) in Alzheimer's Disease," J. Biol. Chem., 270(13):7013-7016 (1995). | ☐ |
| | 193 | HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," Biochimica Biophysica Acta, 1158:120-128 (1993). | ☐ |
| | 177 | HELMUTH, L., "Further Progress on a β-Amyloid Vaccine," Science, 289:375 (2000). | ☐ |
| | 192 | IWATSUBO et al., "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," Neuron, 13:45-53 (1994). | ☐ |
| | 216 | JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," Am. J. of Pathology 138:373-378 (1991). | ☐ |
| | 183 | KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," Biotechnol. Appl. Biochem., 23:227-230 (1996). | ☐ |
| | 195 | KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.2B Specific for the Carboxyl-Terminus of the βA4 Peptide," Annals of NY Acad. Sci., 777:344-355 (1996). | ☐ |
| | 218 | MAJOCHA et al., "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," The J. of Nuclear Med. 33:2184-2189 (1992). | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 3

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

| | | | |
|---|---|---|---|
| | 217 | MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," Proc. Natl. Acad. Sci. USA, 82:4245-4249 (1985). | ☐ |
| | 206 | MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," J. Biol. Chem., 267(24):17082-17088 (1992). | ☐ |
| | 191 | MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β-Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," Am. J. Pathology, 144(5):1082-1088 (1994). | ☐ |
| | ~~144~~ | ~~RASO, V.A., Grant application #1 R43 AG15745-01, (publication date unknown).~~ | ☒ |
| | 209 | RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in Peptide Hormones, J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976). | ☐ |
| | 189 | SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," J. Biol. Chem., 268(33):25239-25243 (1993). | ☐ |
| | 194 | SAIDO et al., "Spatial Resolution of the Primary β-Amyloidogenic Process Induced in Postischemic Hippocampus," J. Biol. Chem., 269(21):15253-15257 (1994). | ☐ |
| | 178 | SCHENK et al., "Therapeutic Approaches Related to Amyloid-β Peptide and Alzheimer's Disease," J. Med. Chem., 38(21):4141-4154 (1995). | ☐ |
| | 182 | SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β-amyloid peptide aggregation," Int. J. Exp. Clin. Invest., 3:130-133 (1996). | ☐ |
| | 184 | SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," Biochem. Mol. Biol. Int., 43(3):601-611 (1997). | ☐ |
| | 185 | SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," Adv. Mol. Cell Biology, 15A:33-45 (1996). | ☐ |
| | 186 | SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown). | ☐ |
| | 179 | SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," J. Neurochemistry, 66:259-265 (1996). | ☐ |
| | 180 | WEN, G.Y., "Alzheimer's Disease and Risk Factors," J. Food Drug Analysis, 6(2):465-476 (1998). | ☐ |
| | 219 | WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," Proc. Natl. Acad. Sci. USA, 82:8729-8732 (1985). | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3158407 v3

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box > [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 1 of 3

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Dale B. Schenk |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

## U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No.[1] | U.S. Patent Document Number | U.S. Patent Document Kind Code[2] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | 196 | 6,150,091 | | Pandolfo et al. | 11-21-2000 | |
| | 1 | 6,057,367 | | Stamler et al. | 05-02-2000 | |
| | 207 | 5,780,587 | | Potter | 07-14-1998 | |
| | 197 | 5,744,368 | | Goldgaber et al. | 04-28-1998 | |
| | 211 | 5,736,142 | | Sette et al. | 04-07-1998 | |
| | 175 | 5,441,870 | | Seubert, et al. | 08-15-1995 | |
| | 181 | 5,270,165 | | Van Nostrand et al. | 12-14-1993 | |
| | 32 | 5,187,153 | | Cordell et al. | 02-16-93 | |
| | 198 | 5,004,697 | | Pardridge | 04-0201991 | |

## FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No.[1] | Foreign Patent Document Office[3] | Number[4] | Kind Code[5] (*if known*) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T[6] |
|---|---|---|---|---|---|---|---|---|
| | 187 | EP | 783 104 | A1 | | 07-09-1997 | | ☐ |
| | 199 | PCT | 00/77178 | A1 | | 12-21-2000 | | ☐ |
| | 188 | PCT | 00/43049 | A1 | | 07-27-2000 | | ☐ |
| | 58 | PCT | 99/27944 | A1 | | 06-10-1999 | | ☐ |
| | 203 | PCT | 99/00150 | A2 | | 01-07-1999 | | ☐ |
| | 202 | PCT | 97/21728 | A1 | | 06-19-1997 | | ☐ |
| | 208 | PCT | 96/28471 | A1 | | 09-19-1996 | | ☐ |
| | 200 | PCT | 95/12815 | A1 | | 05-11-1995 | | ☐ |
| | 201 | PCT | 94/28412 | A1 | | 12-08-1994 | | ☐ |
| | 205 | PCT | 93/04194 | A1 | | 03-04-1993 | | ☐ |
| | 87 | PCT | 89/01343 | A1 | | 02-23-1989 | | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3158407 v3

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 2 of 4

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 99 | BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," Neuron, 19: 939-945 (1997). | ☐ |
| | 100 | BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," Cur. Opin. Genet Develop., 3: 102-109 (1993). | ☐ |
| | 103 | DUFF et al., "Mouse model made," Nature, 373: 476-477 (1995) | ☐ |
| | 104 | ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," J. Neurol. Sciences, 59:341-347 (1983). | ☐ |
| | 109 | GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein," Nature, 373(6514): 523-527 (1995). | ☐ |
| | 111 | GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," J. Exp. Med., 177:1181-1186 (1993). | ☐ |
| | 112 | GLENN et al., "Skin immunization made possible by cholera toxin," Nature, 391: 851 (1998). | ☐ |
| | 113 | GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," Biochemical and Biophysical Research Communications, 120(3): 885-890 (1994). | ☐ |
| | 114 | GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," Biochemical and Biophysical Research Communications, 122(3): 1131-1135 (1984). | ☐ |
| | 117 | GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diptheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," Vaccine, 15(12/13): 1341-1343 (1997). | ☐ |
| | 119 | HANES et al., "New advances in microsphere-based single-dose vaccines," Advanced Drug Delivery Reviews, 28: 97-119 (1997). | ☐ |
| | 120 | HARDY, "Amyloid, the presenilins and Alzheimer's disease," TINS, 20(4): 154-159 (1997). | ☐ |
| | 122 | HSIAO et al., "Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice," Science, 274: 99-102 (1996). | ☐ |
| | 126 | JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," Immun. Rev., 62: 185-216 (1982). | ☐ |
| | 130 | LANGER, "New Methods of Drug Delivery," Science, 249: 1527-1532 (1990). | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3154027 v2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 3 of 4

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

| | | | |
|---|---|---|---|
| | 132 | LEMERE et al., "Mucosal Administration of Aβ Peptide Decreases Cerebral Amyloid Burden In Pd-App Transgenic Mice," Society for Neuroscience Abstracts, vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999). | ☐ |
| | 133 | LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," J. Immunol., 159: 1383-1392 (1997). | ☐ |
| | 134 | LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," Acta. Neurol. Scand., 84:441-444 (1991). | ☐ |
| | 135 | MCGEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," J. Micro. Encap., 14(2): 197-210 (1997). | ☐ |
| | 138 | NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," Am. J. Epidemiol., 145(11): 959-969 (June 1, 1997). | ☐ |
| | 140 | PARECSE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," Neuron, 17:553-565 (September 1996). | ☐ |
| | 141 | PAUL et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers," Eur. J. Immunol., 25: 3521-3524 (1995). | ☐ |
| | 142 | PRIEELS et al., "Synergistic adjuvants for vaccines," Chemical Abstracts, 120(8): pg. 652, column 1, abstract 86406t (1994). | ☐ |
| | 145 | RASO, "Immunotherapy of Alzheimer's Disease," Immunotherapy Weekly, Abstract (April 2, 1998). | ☐ |
| | 149 | SELKOE, D.J., "Imaging Alzheimer's Amyloid," Nat. Biotech., 18:823-824 (2000). | ☐ |
| | 150 | SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," J. Neuropathol. Exp. Neurol., 53(5): 438-447 (1994). | ☐ |
| | 151 | SELKOE, "Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease," Trends in Neurosciences, 16(10): 403-409 (1993). | ☐ |
| | 156 | SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids," Nature, 359: 325-327 (1992). | ☐ |
| | 158 | SMITS et al., "Prion Protein and Scrapie Susceptibility," Vet. Quart., 19(3): 101-105 (1997). | ☐ |
| | 159 | SOLOMON et al., "Disaggregation of Alzheimer β-amyloid by site-directed mAb," PNAS, 94:4109-4112 (1997). | ☐ |
| | 160 | SOLOMON et al., "Monoclonal antibodies inhibit in *vitro* fibrillar aggregation of the Alzheimer β-amyloid peptide," PNAS, 93:452-455 (1996). | ☐ |
| | 161 | SOLOMON, A. "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown). | ☐ |
| | 163 | STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against *Plasmodium Falciparum* Malaria", N. Engl. J. Med., 336(2): 86-91 (1997). | ☐ |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

[1] EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

Please type a plus sign (+) inside this box [+]

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet 4 of 4

| *Complete if Known* | |
|---|---|
| Application Number | 09/322,289 |
| Filing Date | May 28, 1999 |
| First Named Inventor | Schenk, Dale B. |
| Group Art Unit | 1647 |
| Examiner Name | S. Turner |
| Attorney Docket Number | 15270J-004740US |

| | | | |
|---|---|---|---|
| | 164 | STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," PNAS, 94: 13287-13292 (1997). | ☐ |
| | 172 | WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," Curr. Opin. Neurobiol., 7: 695-700 (1997). | ☐ |
| | 173 | WOOD et al., "Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease," PNAS, 94: 1550-1555 (1997). | ☐ |
| | 174 | ~~Human Immunology & Cancer Program brochures from The University of Tennessee Medical Center/Graduate School~~ of Medicine, Knoxville, Tennessee (publication date unknown). | ☐ |

| Examiner Signature | /Daniel Kolker/ | Date Considered | 12/09/2010 |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3154027 v2